Evidence map›Paper›PMID 31745133›Full record

ArticleScientific reports2019

Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease.

Mikhail V Voronin, Ilya A Kadnikov, Dmitry N Voronkov, Sergey B Seredenin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Multi-Target Directed Ligands (MTDLs) Binding the σInternational journal of molecular sciences · 2021
    Review
  7. Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole.International journal of molecular sciences · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Chaperone Sigma1R and Antidepressant Effect.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mikhail V VoroninFederal State Budgetary Institution "Research Zakusov Institute of Pharmacology", Department of Pharmacogenetics, Baltiyskaya street 8, Moscow, 125315, Russian Federation.ORCID http://orcid.org/0000-0003-2477-0563
Ilya A KadnikovFederal State Budgetary Institution "Research Zakusov Institute of Pharmacology", Department of Pharmacogenetics, Baltiyskaya street 8, Moscow, 125315, Russian Federation. ikadnikov@gmail.com.ORCID http://orcid.org/0000-0001-8202-3967
Dmitry N VoronkovResearch Center of Neurology, Laboratory of Functional Morphochemistry, Volokolamskoe Highway 80, Moscow, 125367, Russian Federation.ORCID http://orcid.org/0000-0001-5222-5322
Sergey B SeredeninFederal State Budgetary Institution "Research Zakusov Institute of Pharmacology", Department of Pharmacogenetics, Baltiyskaya street 8, Moscow, 125315, Russian Federation.
Institute of Pharmacology Russian Academy of Medical Sciences · RUResearch Center of Neurology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease with limited treatment options. Therefore, the identification of therapeutic targets is urgently needed. Previous studies have shown that the ligand activation of the sigma-1 chaperone (Sigma1R) promotes neuroprotection. The multitarget drug afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride) was shown to interact with Sigma1Rs and prevent decreases in striatal dopamine in the 6-hydroxydopamine (6-OHDA)-induced parkinsonism model. The aim of the present study was to elucidate the role of Sigma1Rs in afobazole pharmacological activity. Using ICR mice we found that administration of afobazole (2.5 mg/kg, i.p.) or selective agonist of Sigma1R PRE-084 (1.0 mg/kg, i.p.) over 14 days normalizes motor disfunction and prevents decreases in dopamine in the 6-OHDA-lesioned striatum. Afobazole administration also prevents the loss of TH + neurons in the substantia nigra. The pre-administration of selective Sigma1R antagonist BD-1047 (3.0 mg/kg, i.p.) abolishes the activity of either afobazole or PRE-084, as determined using the rotarod test and the analysis of striatal dopamine content. The current study demonstrates the contribution of Sigma1Rs in the neuroprotective effect of afobazole in the 6-OHDA model of Parkinson's disease and defines the therapeutic perspective of Sigma1R agonists in the clinic.

Indexed as

AnimalsBenzimidazolesCorpus StriatumDisease Models, AnimalDopamineEthylenediaminesMaleMiceMice, Inbred ICRMorpholinesNeuronsNeuroprotectionNeuroprotective AgentsOxidopamineParkinson DiseaseReceptors, sigma2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylateBenzimidazolesDopamineEthylenediaminesMorpholinesN-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiaminNeuroprotective AgentsOxidopamineReceptors, sigmaSigma-1 Receptor

Identifiers

PMID31745133
PMCPMC6863824
OpenAlexW2990111605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.